Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)
Silo Pharma (NASDAQ: SILO) announced on October 6, 2025 that it purchased ResearchCoin (RSC) as part of an expanded digital-assets treasury strategy to gain exposure to decentralized science (DeSci).
RSC is the native token of ResearchHub, a platform co-founded in 2019 by Coinbase CEO Brian Armstrong, designed to reward sharing, peer review, and curation of scientific knowledge. Silo characterized the move as an effort to diversify assets and participate in token-based models that could unlock value in the global research economy through tokenization of funding and intellectual property.
The announcement frames DeSci as a long-term growth opportunity that could allow earlier liquidity and exit options for research-backed innovations, but the company did not disclose the size, valuation, or timing of the RSC purchase.
Silo Pharma (NASDAQ: SILO) ha annunciato il 6 ottobre 2025 di aver acquistato ResearchCoin (RSC) nell'ambito di una strategia ampliata di tesoreria di asset digitali per ottenere esposizione alla scienza decentralizzata (DeSci).
RSC è il token nativo di ResearchHub, una piattaforma co-fondata nel 2019 dal CEO di Coinbase Brian Armstrong, progettata per premiare condividere, la revisione tra pari e la curatela della conoscenza scientifica. Silo ha descritto l'operazione come un impegno a diversificare gli asset e partecipare a modelli basati su token che potrebbero sbloccare valore nell'economia globale della ricerca attraverso la tokenizzazione di finanziamenti e proprietà intellettuale.
L'annuncio presenta DeSci come una opportunità di crescita a lungo termine che potrebbe consentire una liquidità precoce e opzioni di uscita per innovazioni supportate dalla ricerca, ma l'azienda non ha divulgato la dimensione, la valutazione o i tempi dell'acquisto di RSC.
Silo Pharma (NASDAQ: SILO) anunció el 6 de octubre de 2025 que adquirió ResearchCoin (RSC) como parte de una estrategia ampliada de tesorería de activos digitales para obtener exposición a la ciencia descentralizada (DeSci).
RSC es el token nativo de ResearchHub, una plataforma cofundada en 2019 por el director ejecutivo de Coinbase, Brian Armstrong, diseñada para recompensar compartir, revisión por pares y curación de conocimientos científicos. Silo describió la operación como un esfuerzo por diversificar activos y participar en modelos basados en tokens que podrían desbloquear valor en la economía global de la investigación mediante la tokenización de financiamiento y propiedad intelectual.
El anuncio presenta DeSci como una oportunidad de crecimiento a largo plazo que podría permitir una liquidez temprana y opciones de salida para innovaciones respaldadas por la investigación, pero la empresa no reveló el tamaño, la valoración ni el momento de la compra de RSC.
Silo Pharma (나스닥: SILO)가 2025년 10월 6일에 ResearchCoin(RSC)을 매입했다고 발표했습니다. 이는 탈중앙화 과학(DeSci)에 대한 노출을 얻기 위한 확장된 디지털 자산 금고 전략의 일환입니다.
RSC는 ResearchHub의 기본 토큰으로, 2019년 Coinbase CEO 브라이언 암스트롱이 공동 설립한 플랫폼으로, 과학 지식의 공유, 동료 검토, 큐레이션을 보상하도록 설계되었습니다. Silo는 이 조치를 자산 다변화의 노력이자 자금 조달과 지적 재산의 토큰화를 통해 글로벌 연구 경제의 가치를 열 수 있는 토큰 기반 모델에의 참여로 설명했습니다.
발표는 DeSci를 연구 지원 혁신에 대한 초기 유동성과 매각 옵션을 가능하게 할 수 있는 장기 성장 기회로 간주하지만, 회사는 RSC 매입의 규모, 평가액 또는 시점을 공개하지 않았습니다.
Silo Pharma (NASDAQ: SILO) a annoncé le 6 octobre 2025 qu'elle avait acheté ResearchCoin (RSC) dans le cadre d'une stratégie élargie de trésorerie d'actifs numériques pour s'exposer à la science décentralisée (DeSci).
RSC est le jeton natif de ResearchHub, une plateforme cofondée en 2019 par le PDG de Coinbase, Brian Armstrong, conçue pour récompenser le partage, l'évaluation par les pairs et la curation des connaissances scientifiques. Silo a décrit cette démarche comme un effort de diversification des actifs et de participation à des modèles basés sur les jetons qui pourraient débloquer de la valeur dans l'économie mondiale de la recherche via la tokenisation du financement et de la propriété intellectuelle.
L'annonce présente DeSci comme une opportunité de croissance à long terme qui pourrait permettre une liquidité précoce et des options de sortie pour les innovations soutenues par la recherche, mais l'entreprise n'a pas divulgué l'ampleur, l'évaluation ou le calendrier de l'achat de RSC.
Silo Pharma (NASDAQ: SILO) gab am 6. Oktober 2025 bekannt, ResearchCoin (RSC) im Rahmen einer erweiterten Treasury-Strategie für digitale Vermögenswerte erworben zu haben, um sich der dezentralen Wissenschaft (DeSci) auszusetzen.
RSC ist der native Token von ResearchHub, einer Plattform, die 2019 vom Coinbase-CEO Brian Armstrong mit gegründet wurde und darauf abzielt, das Teilen, die Begutachtung durch Gleichgesinnte und die Kuratierung wissenschaftlichen Wissens zu belohnen. Silo führte die Maßnahme als Bestreben an, Vermögenswerte zu diversifizieren und an tokenbasierten Modellen teilzunehmen, die durch Tokenisierung von Finanzierung und geistigem Eigentum Wert in der globalen Forschungswirtschaft freisetzen könnten.
Die Ankündigung beschreibt DeSci als langfristige Wachstumschance, die frühzeitige Liquidität und Ausstiegsoptionen für forschungsbasierte Innovationen ermöglichen könnte, aber das Unternehmen hat Größe, Bewertung oder Timing des RSC-Kaufs nicht offengelegt.
Silo Pharma (سيرتك: SILO) أعلنت في 6 أكتوبر 2025 أنها اشترت ResearchCoin (RSC) كجزء من استراتيجية احتياطي أصول رقمية موسعة للوصول إلى العلوم اللامركزية (DeSci).
RSC هو الرمز الأصلي لـ ResearchHub، منصة تأسست في 2019 بواسطة الرئيس التنفيذي لـ Coinbase براين أرمسترونغ، مصممة لمكافأة المشاركة، ومراجعة الأقران، وتنظيم المعرفة العلمية. وصفت Silo هذه الخطوة بأنها جهد لتنويع الأصول والمشاركة في نماذج قائمة على الرموز قد تفتح قيمة في اقتصاد البحث العالمي من خلال ترميز التمويل والملكية الفكرية.
الإعلان يصور DeSci كفرصة نمو طويلة الأجل قد تتيح سيولة مبكرة وخيارات خروج للابتكارات المدعومة بالبحوث، لكن الشركة لم تكشف عن الحجم أو التقييم أو توقيت شراء RSC.
Silo Pharma (纳斯达克: SILO)宣布在 2025年10月6日购买 ResearchCoin (RSC)，作为扩大的数字资产库战略的一部分，以获得对去中心化科学（DeSci）的暴露。
RSC 是 ResearchHub 的原生代币，该平台于 2019 年由 Coinbase 首席执行官 布莱恩·阿姆斯特朗共同创立，旨在奖励分享、同行评审和科学知识的策展。Silo 将此举描述为多样化资产并参与基于代币的模型的努力，这些模型通过对资金和知识产权的代币化，可能解锁全球研究经济的价值。
公告将 DeSci 视为一项长期增长机会，可能为研究支持的创新提供更早的流动性和退出选项，但公司未披露 RSC 购买的规模、估值或时间。
- None.
- None.
Insights
Silo bought ResearchCoin (RSC) to diversify its digital-asset treasury; the move is strategically neutral until allocation and outcomes are disclosed.
Silo Pharma expanded its digital-assets treasury by purchasing ResearchCoin (RSC), the native token of ResearchHub, a decentralized science platform co-founded by Brian Armstrong. The transaction changes the company’s balance-sheet exposure from purely biotech development to include tokenized, protocol-level assets that aim to reward scientific contributions.
The announcement depends on several disclosed variables that remain unspecified in the release: the size of the purchase, the percentage of total treasury allocated to RSC, and any governance or lockup terms tied to the tokens. These missing facts materially affect balance-sheet risk, disclosure requirements, and investor dilution of focus between biotech operations and crypto treasury management.
Watch for three concrete items in the near term: the exact treasury allocation to RSC and any subsequent token purchases, formal disclosure of purchase price and accounting treatment, and any governance rights or vesting attached to the tokens; monitor these over the next
Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong
SARASOTA, FL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced its initial purchase of ResearchCoin (RSC) as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. RSC is the native token of ResearchHub, a decentralized platform designed to advance scientific collaboration and discovery. ResearchHub was co-founded in 2019 by Coinbase CEO, Brian Armstrong.
“By securing a position in RSC, we are participating in the growing decentralized science (DeSci) movement while pursuing asset diversification and potential appreciation for shareholders,” said Eric Weisblum, CEO of Silo Pharma. “Our investment in ResearchCoin demonstrates our interest in modernizing scientific research and collaboration and supporting blockchain-driven innovation as a pillar for biomedical discovery.”
Like DeFi, DeSci is a Web3 movement that emphasizes decentralization blockchain technologies and token-based economics. RSC tokens are designed to reward and encourage the sharing, review and curation of scientific knowledge. The ResearchHub platform enables a global community of researchers to collaborate, publish, and peer review in a transparent, tokenized environment—with a goal of accelerating discovery while ensuring contributors are recognized and rewarded for their work.
DeSci represents a transformative growth opportunity in the scientific research sector. The estimated trillion-dollar global research economy—currently tied up in grants, universities, and pharmaceutical pipelines—can potentially be unlocked and made liquid through tokenization. By tokenizing research funding and intellectual property, DeSci creates potential profit opportunities years before traditional biotech exits. Investors may be able to capture upside earlier, exit more flexibly, and access new avenues of growth in the biotech sector.
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What did Silo Pharma announce about ResearchCoin (RSC) on October 6, 2025?
How does the RSC purchase affect Silo Pharma's treasury strategy (SILO)?
Who created ResearchCoin and ResearchHub referenced by Silo Pharma (SILO)?
Did Silo Pharma disclose the monetary size or percentage of its RSC purchase (SILO)?
What is decentralized science (DeSci) and why is Silo Pharma investing in RSC (SILO)?
Will Silo Pharma's RSC purchase immediately change shareholder dilution or guidance for SILO?
